Table 3.

Summary of studies describing duration of viral detection as days after hospitalization.

No	Author	Design	Threshold Gene	Age *	Clinical severity	Reported Treatment	Size	Sampling Location	2 Consecutive negatives Day -1		2 Consecutive negatives Last positive
									Mean	SD	Mean	SD
34	Chen [42]	Retrospective	WHO	51•0	Mild	NS	2	Pharyngeal	4•5	2•1	3•5	2•1
							2	Stool	10•5	3•5	9•5	3•5
					Moderate		30	Pharyngeal	6•6	4•3	5•6	4•3
							17	Stool	11•7	7•2	9•9	7•2
					Severe		10	Pharyngeal	13•4	3•2	10•	3
							9	Stool	8	4•9	14•2	6•1
35	Lo [43]	Case series	Ct > 38 ORF1ab, N	54•0	Mild	L/R	2	Faeces	16•5	0•7	15•0	1•4
							2	Nasopharyngeal	13•0	5•7	12•0	7•1
					Moderate-Severe		7	Faeces	13•7	3•5	12•1	3•6
							8	Nasopharyngeal	12•5	6•6	12•0	6•9
36	Xing [44]	Case series	[45]	5•0	Mild	aIFN +Ribavirin	3	Faeces	12•7	2•5
							3	Throat	18•7	12•1
37	Xu [46]	Case series	Ct > 40 ORFab1, N	51•0	Mild	NS	47	Throat	11•4	5•6

No recurrence was reported for these studies. Blank columns apply if sampling was daily (value of Day -1 equals last positive) or no recurrence occurred.

aIFN: Alpha interferon, Ct = Threshold cycle, L/R: Lopinavir/Ritonavir, N: Truncated nucleocapsid, ORF: Open reading frame, SD: Standard deviation, WHO: World health organization;

^⁎Age displayed as median in years